Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro.

Sebastian SchloerLinda BrunotteAngeles Mecate-ZambranoShuyu ZhengJing Tang Stephan Ludwig Ursula Rescher

Published in: British journal of pharmacology (2021)

Itraconazole-remdesivir and fluoxetine-remdesivir combinations are promising starting points for therapeutic options to control SARS-CoV-2 infection and severe progression of COVID-19.

Keyphrases

respiratory syndrome coronavirus
coronavirus disease
sars cov
drug induced
emergency department
combination therapy